

IN THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the Application.

Listing of the Claims:

20-21/1-8

Claim 1-19 (cancelled)

1
Claim ~~20~~ (currently amended): A method of inhibiting the binding of ~~Tsg101~~ the human tumor susceptibility gene 101 protein (Tsg101) to ~~HIV GAG~~ the human immunodeficiency virus (HIV) GAG polyprotein (HIV GAG) comprising contacting Tsg101 with an antibody immunoreactive with the [[UEV]] ubiquitin E2 variant (UEV) domain of Tsg101, in the presence of said HIV GAG, wherein said antibody inhibits said binding.

→ p. 72
SUPPORT

2
Claim ~~21~~ (currently amended): The method of claim ~~20~~, wherein said binding of Tsg101 to HIV GAG occurs between the UEV domain of Tsg101 and the ~~late domain of HIV GAG~~ late assembly domain of HIV GAG p6.

3
Claim ~~22~~ (previously presented): The method of claim ~~20~~, wherein said antibody is selectively immunoreactive with the UEV domain of Tsg101.

4
Claim ~~23~~ (previously presented): The method of claim ~~20~~, wherein said antibody is a polyclonal antibody.

5
Claim ~~24~~ (previously presented): The method of claim ~~20~~, wherein said antibody is a monoclonal antibody.

435/5

C 12 Q 1170

424/208.1

A 61 K 39/21

Page 2 of 10

103-107

11/17/06

6 1
Claim ~~25~~ (previously presented): The method of claim ~~20~~, wherein said antibody is an antibody fragment.

7 1
Claim ~~26~~ (previously presented): The method of claim ~~20~~, wherein said antibody is a single chain antibody.

8 1
Claim ~~27~~ (previously presented): The method of claim ~~20~~, wherein said antibody is a humanized antibody.

IN THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the Application.

Listing of the Claims:

Claim 1-19 (cancelled)

Claim 20 (currently amended): A method of inhibiting the binding of ~~Tsg101~~ the human tumor susceptibility gene 101 protein (Tsg101) to ~~HIV GAG~~ the human immunodeficiency virus (HIV) GAG polyprotein (HIV GAG) comprising contacting Tsg101 with an antibody immunoreactive with the [[UEV]] ubiquitin E2 variant (UEV) domain of Tsg101, in the presence of said HIV GAG, wherein said antibody inhibits said binding.

Claim 21 (currently amended): The method of claim 20, wherein said binding of Tsg101 to HIV GAG occurs between the UEV domain of Tsg101 and the ~~late domain of HIV GAG~~ late assembly domain of HIV GAG p6.

Claim 22 (previously presented): The method of claim 20, wherein said antibody is selectively immunoreactive with the UEV domain of Tsg101.

Claim 23 (previously presented): The method of claim 20, wherein said antibody is a polyclonal antibody.

Claim 24 (previously presented): The method of claim 20, wherein said antibody is a monoclonal antibody.

Claim 25 (previously presented): The method of claim 20, wherein said antibody is an antibody fragment.

Claim 26 (previously presented): The method of claim 20, wherein said antibody is a single chain antibody.

Claim 27 (previously presented): The method of claim 20, wherein said antibody is a humanized antibody.